EV Warning: Bezos-Backed Slate Auto Disruption Ahead
The seemingly staged drama between President Trump and Tesla (TSLA) CEO Elon Musk might distract shareholders. TSLA stock rebounded from a brutal 14% daily drop last week. Speculators bet that Tesla’s prospects will recover, despite global boycotts against the firm.Tesla’s growth is not assured. The cyber cab, self-driving software, and ties to AI are not firm. In addition, the CEO of China’s Geely, Daniel Donghui Li, said that the global EV market faces serious overcapacity.Former Amazon (AMZN) CEO Jeff Bezos might disrupt the EV market further. Bezos backed Slate, an EV startup. This firm has plenty of prototypes, a lab to test its designs, and vehicles that the firm has crash-tested.Slate wants to release a no-frills, affordable EV at $20,000. That assumes a $7,500 federal EV tax credit on the under $27,500 price tag. The company has more than 100,000 reservations, with customers paying a $50 deposit.Slate raised $700 million in its first two rounds of financing. The company has an edge over the competition. Unlike Rivian (RIVN) and Lucid Motors (LCID), Slate is capital-light. It believes that it does not need billions in spending to achieve mass-scale production. The company’s vehicle benefited from superior engineering and production. As a result, people will get an affordable model.Markets are starting to worry: General Motors (GM) is going down while Ford Motor (F) is trading in a range. Stellantis (STLA) is down by 24.4% so far in 2025.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


